Many authorities now advocate that the first-line assessment of thyroid function should be measurement of thyrotropin (TSH). The latest serum TSH assays (third generation) are more sensitive than the second generation but the reagents are more costly. We have examined whether overall assay reagent costs would be higher or lower with a third-generation assay, in a laboratory that serves a population of almost 500000. In a prospective study over six weeks, 505 samples with a second-generation serum TSH less than 0.5 mU/L (303 for screening and 202 for monitoring thyroxine therapy) had an additional third-generation TSH analysis.
INTRODUCTION
Measurement of serum thyrotropin (TSH) is being advocated for first-line assessment of thyroid function both in screening for suspected new thyroid diseasel and the monitoring of thyroxine (T4) therapy in patients with existing thyroid disease2.
There has been a rapid development of serum TSH assays, each new generation with ten-fold greater sensitivity3. Although sensitivity, in analytical terms, is often held to be the minimum concentration distinguishable from zero, the term functional sensitivity has more practical value as it represents the minimum concentration above which the interassay coefficient of variation is less than 20%4. This represents the limit below which the reliability of a given result is questionable. The first-generation radioimmunoassays, launched in the late 1 960s, had a functional sensitivity limit of I to 2 mU/L. The current widely used immunometric or sandwich assays (second generation) have a functional sensitivity of 0.1 mU/L. Further developments have led to third-generation chemiluminescence assays, with about a ten-fold improvement in functional sensitivity. This increasing level of sensitivity, with the potential introduction of a fourthgeneration assay5, has occurred without any determination of the sensitivity required for testing of thyroid disease in the community. New assays are being adopted widely without full evaluation of the costs and benefits.
The laboratory practice at North Staffordshire District General Hospital, which serves a population of almost 500 000, was to measure free thyroxine (FT4) and TSH (with a second-generation assay) on all specimens requiring a test of thyroid function. In view of the increasing requests for thyroid function tests, the laboratory considered changing to a single TSH-led service. The current laboratory reagent cost for a second-generation TSH assay and FT4 on all samples is £34 000, of which £20 000 is spent on the FT4 assays. The additional annual reagent cost of a third-generation instead of second-generation TSH assay on all specimens would be £11 000. We sought to determine whether such a substitution would reduce costs. In a prospective study over six weeks, all samples from patients categorized by a second-generation assay as having serum TSH less than 0.5 mU/L (CoTube IRMA, Bio-Rad, Hercules, California, USA) had an additional third-generation TSH analysis (Immulite, Euro-DPC, Llanberis, UK). The number of samples with TSH less than 0.5mU/L was 580 (14% of total). This level of serum TSH was chosen because it was likely to include all thyrotoxic patients. Those patients with pituitary disease, those on thionamide or amiodarone therapy, and those in whom there was insufficient clinical information were excluded (n=75).
METHODS
The reference ranges, defined by 95% confidence intervals for the healthy population, were 0.3 to 4.8 mU/L for the second-generation TSH assay and 0.4 to 4.0mU/L for the third-generation assay. The lower limits of the assays quoted by the manufacturers were 0.02 and 0.002 mU/L, respectively. The clinically applicable or functional sensitivities, defined as the lowest value with a less than 20% interassay coefficient of variation4, were 0.1 and 0.01 mU/L, respectively. The respective interassay coefficients of variation were 14.1% and 12.9% at a serum TSH of 0.5 mU/L.
Thyrotropin suppression was defined for both assays by choice of a serum TSH level below which all new cases of thyrotoxicosis occurred-i.e. 100% sensitivity. The definition of suppression applied in this study was 0.1 mU/L in the second-generation TSH assay and 0.01 mU/L in the third-generation assay. A serum FT4 measurement (Amerlex, MAB, Amersham, Berkshire, UK; reference range 10-27 pmol/ L) was performed on screening samples if the second-generation TSH level was less than 0.1 mU/L, to exclude thyrotoxicosis. Over-replacement with T4 was defined as a suppressed serum TSH and FT4 greater than 28 pmol/L. A cost analysis determined whether the improved sensitivity at the lower end of the normal range would reduce the number of confirmatory FT4 measurements sufficiently to offset the increased reagent costs. The significance of differences between groups was determined with Student's t-test.
RESULTS
In North Staffordshire the annual number of requests rose from 19 997 in 1984 to over 35 000 in 1995. The proportion of requests from primary care increased from 30% in 1984 to 61% in 1995. In 1995 the 35 000 samples were split between GPs (61%), hospital outpatients (30%) and inpatients (9%). About 80% were tests for suspected new thyroid disease and 20% for monitoring of T4 treatment.
In the six-week study period a second-generation assay identified 303 samples tested for new thyroid disease in which serum TSH was less than 0.5 mU/L; 42% of these had been requested by GPs. 39 new cases of thyrotoxicosis were confirmed by high FT4 and free triiodothyronine (FT3) levels and clinical criteria. All these patients had serum TSH below the defined level of suppression in both assays. In total, 101 were suppressed according to the second-generation assay and 69 according to the thirdgeneration assay; so an extra 32 FT4 measurements were required to exclude thyrotoxicosis with the secondgeneration assay. The median FT4 level was significantly higher in those samples with a suppressed TSH in the thirdgeneration assay (26.7pmol/L) than in those in which only the second-generation TSH was suppressed (19.6pmol/L) (P=0.004).
Of 878 samples tested for monitoring of T4 therapy, 23% had a serum TSH less than 0.5 mU/L. Of these 202 samples, 75% had originated from general practice. In total, 109 were suppressed (less than 0.1 mU/L) in the secondgeneration TSH assay and 42 in the third-generation assay (less than 0.01 mU/L), so 67 extra FT4 measurements were needed to exclude over-treatment with the secondgeneration assay (Table 1) . Of the 18 samples with a raised serum FT4, only 2 had a suppressed second-generation but not third-generation TSH assay but neither had a FT4 greater than 30pmol/L. The median FT4 was significantly higher in those samples with a suppressed third-generation TSH assay (25.0 pmol/L) than *in samples where the second-generation but not third-generation TSH was suppressed (20.9pmol/L) (P=0.0002).
The expected annual cost of the reagents was extrapolated from this six-week period. The cost of using a first-line second-generation TSH-led service, with supplementary FT4 measurement where the TSH is less than 0.1 mU/L, was just over £15 000. On the other hand if a third-generation TSH assay was used, despite fewer FT4 measurements, the total cost was £27 500. The current cost of using a second-generation assay and FT4 on all samples is £34 000, and use of a third-generation assay and FT4 on all specimens would be £45 000.
Reagents are only one factor determining the cost of an investigative service, so we also looked at equipment and labour costs. Although the two generations of TSH assays use different technologies, the cost of the equipment when budgeted over a seven-year period differed very little at £12 000 per annum. However, in practice the gamma counting equipment used for the second-generation assay would have a considerably longer service life than seven years, so there would be further savings of about £6000 a year. Direct labour costs were calculated for our workload at 24 hours per week in technician time for the secondgeneration assay and 21 hours for the third-generation assay; the additional working time equates to an annual expenditure of £1500.
DISCUSSION
Since 1984 the requests for testing of thyroid function to this large district general hospital have increased substantially, particularly the proportion from primary care. This study suggests that an increasing number of individuals are being tested for suspected new thyroid disease in the community. The explanation may lie either in greater awareness of the need to exclude thyroid disease or in more indiscriminate testing of thyroid function, for example in 'well-woman' screening clinics. The evidence from epidemiological studies is that general testing of the population will detect few cases of overt hyperthyroidism and is unjustified6. The case for detection of subclinical hyperthyroidism, which will be an inevitable consequence of screening with serum TSH determinations, is even less clear7. In a community-based UK study, serum TSH values below the lower limit of normal (0.1-0.5 mU/L) were found in about 5% of men and women aged over 60 years but few developed overt hyperthyroidism at one year and in many serum TSH returned to normal8. Most studies indicate that serum TSH measurements are the single most specific test of thyroid status and an efficient first-line test of thyroid function in ambulatory patients9"0. Measurement of thyroid hormone concentrations is required in patients with undetectable TSH to distinguish between subclinical and overt hyperthyroidism. However, below the functional sensitivity level of the secondgeneration TSH assay, 0.1 mU/L, the interassay precision rises appreciablyl" and not every patient with hyperthyroidism will have a completely suppressed TSH Table 2 Estimated annual expenditure on reagents with secondor third-generation thyrotropin (TSH) assay led service study all new cases of thyrotoxicosis, confirmed by raised FT4 and FT3 concentrations and supporting clinical criteria, occurred in patients with TSH levels below the defined limits of functional sensitivity in both assays.
The new third-generation assays, most of which use novel non-isotopic chemiluminescence labels, have improved functional sensitivity ten-fold over radioisotope labelled immunometric methods4. This should give a more reliable distinction between the profoundly suppressed serum TSH levels of hyperthyroidism and the less pronounced serum TSH reductions prevalent in thyroxine-treated patients or euthyroid patients with nonthyroidal illness. However, studies comparing the two assays have shown substantial overlap between these two groups and no advantage has emerged for the thirdgeneration'
As assays become more sensitive and innovative, their cost increases. We wanted to determine whether the higher cost is offset by a decrease in the number of confirmatory free hormone measurements, looking at equipment and labour as well as expenditure on reagents. In this costanalysis the difference in labour costs was small, since the labour element was principally time involved in sample handling. This would not necessarily be true in other laboratories. For example, as workload declines nonisotopic systems may become more cost-effective, since in general they deal with small numbers of tests more efficiently. The annual equipment cost for the secondgeneration TSH assay would probably be much less than that of the complex random access automated analysers of the third-generation assay because of its longer life. With the large number of samples sent for thyroid function testing in our laboratory, the costs of these aspects of the two methods for measuring serum TSH are similar but in general favour the second generation. This is amplified when we look at reagent costs, which account for a large proportion of total expenditure. However, these conclusions are heavily dependent on the manufacturer's reagent pricing strategy, and the costs quoted to the hospital laboratory have been taken as the relevant measure. The market price of the third-generation assay may differ from the true cost of the reagents to the manufacturers, who may be offsetting their research and development expenditure.
This exercise is therefore a financial rather than an economic appraisal.
This study has shown that the second-generation assay required only 11 % more FT4 measurements to exclude thyrotoxicosis (less than 1% of total screening workload). This resulted in a saving of 42% of the laboratory reagent budget compared with third-generation screening. For monitoring of patients on thyroxine treatment, 33% more FT4 measurements were required (8% of extra T4 monitoring workload) and the calculated saving was 53%.
Although the FT4 levels were significantly higher in those samples in either group with a suppressed third-generation TSH, the majority were still below the upper end of the normal range.
This laboratory has now switched to a single TSH-led service for testing of suspected new thyroid disease. By using a second and not third-generation TSH assay, we made an overall saving in the reagent budget of 45%. The annual cost of the third generation TSH assay would have to be within £500 (i.e. the cost of the extra FT4 measurements) to justify its use in place of the secondgeneration assay. Despite the higher sensitivity of the thirdgeneration TSH assays, there seems little justification for their use for exclusion of hyperthyroidism or thyroxine over-treatment in a predominantly community-based sample.
